The CDK4/6 inhibitor palbociclib (Ibrance) demonstrated it was active and well-tolerated in a phase II interim analysis of patients with brain metastases harboring alterations in the CDK pathway, according to a presentation at the 24th Annual Meeting and Education Day of the Society of NeuroOncology.
At the 24th Annual Meeting and Education Day of the Society of NeuroOncology, Victor Levin, MD, spoke with Targeted Oncology about the STELLAR trial.
Yuma Regional Medical Center Cancer Center has implemented a genetic cancer screening and testing for their patients through collaboration with Myriad Genetics, a molecular diagnostic testing company, according to a presentation by Erica Martinez, RN, OCN, at the Association of Community Cancer Centers’ 2019 National Oncology Conference. After partnering with Myriad Genetics, the cancer center saw a 4-fold increase in genetic testing of patients with cancer in the first 4 months, which led to a change in clinical management in 20% of those cases.
During a <em>Targeted Oncology </em>live case-based peer perspectives live discussion, Anna C. Pavlick, DO, MS, explained to a group of physicians best practices for the diagnosis and management of patients with metastatic melanoma. Pavlick, discussed treatment options between immunotherapy and targeted therapy based on the case scenario of a patient with <em>BRAF </em>wild-type metastatic melanoma.
Barbara Pro, MD, spoke with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion about the diagnosis, prognosis, and treatment of patients with Hodgkin lymphoma based on the case of a young woman with classic Hodgkin lymphoma.
The American Oncology Network, LLC highlights its achievements while celebrating its first year of helping community oncologists.
Patients with non–small cell lung cancer on radiotherapy had a worse overall survival when a hurricane disaster was declared for their hospital than patients who did not experience a declaration, according to a study published in<em> JAMA</em>.
The use of more aggressive frontline chemotherapy regimens plus biologics for the treatment of patients with meta-static colorectal cancer may be warranted based on mutational status, tumor sidedness, treatment goals, prognosis, and patient disposition, according to a presentation by Axel Grothey, MD, at the 14th Annual New Orleans Summer Cancer Meeting, held July 19 to 21, 2019, in Louisiana.
In a recent review of the 5-year outcomes from the COMBI-d and COMBI-v trials published in the New England Journal of Medicine, investigators saw long-term benefit with the use of dabrafenib plus trametinib as first-line treatment in about one-third of patients with unresectable or metastatic melanoma and BRAF V600E or V600K mutations.
Florida Cancer Specialists & Research Institute has announced an oncology-focused initiative with Cigna as a part of the Cigna Collaborative Care. The Cigna Oncology Focus program's main goal is to provide quality care and contain costs for people with cancer. It also uses incentives to encourage healthcare professionals to improve affordability, as well as patients health and overall experience.
The American Society of Hematology has chosen Philip Greenberg, MD, to receive the 2019 E. Donnall Thomas Lecture and Prize for his work in immunotherapy.
Jorge Cortes, MD Cortes discussed frontline treatment options for patients with CML with <em>Targeted Oncology</em> ahead of a debate on optimal frontline regimens for chronic myeloid leukemia at the <em>3rd Annual</em> Live Medical Crossfire: Hematologic Malignancies, hosted by Physicians’ Education Resource.<br />
The American Oncology Network, LLC will be acquiring a new practice from Ohio in August.
Carey K. Anders, MD, spoke with <em>Targeted Oncology</em> about treatment options emerging to improve outcomes for patients with metastatic breast cancer and secondary brain metastases.
Laura Dawson, MD, FRCPC, FASTRO, has been selected as the president-elect of the American Society for Radiation Oncology and will begin her term at the society’s 61st Annual Meeting, which is being held in Chicago, Illinois on September 15-18.